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inclusion were Mehran Class I, II, or III lesions less than 30 mm in length, 50-99% diam- 
eter, covered in their entirety by no more than 2 contiguously placed stents inserted a 
minimum of 90 days prior to enrollment. After pre-dilation,15 mm NIRx TM Conformer Cor- 
onary Stent(s) with 1.0 Hg/mm2 (loaded drug/stent surface area) Paclitaxel in a slow- 
release formulation were implanted. Pre- and post- stent intra-vascular ultrasound 
(IVUS) was performed. The primary endpoint was the 30-day incidence of major cardiac 
events (MACE) defined as death, myocardial infarction, or target vessel revasculariza- 
tion. 
Results: The study has completed enrollment. All 29 patients had successful stent 
implantation. Fourteen patients received 2 stents; the rest received 1. Two peri-proce- 
dural MACE events have been reported at this time. Planned follow-up will be at 1,6, 12 
months and then annually. Repeat tVUS and angiography will be performed 6 months 
after the baseline procedure. 
Conclusions: Early feasibility data show promise for the use of polymer-controlled Pacli- 
taxel-eluting stents to treat ISR, Six month clinical and angiographic data will be reported 
in March 2002. 
1174-16 Sirolimus Coated Stent Versus Bare Stent: 
Angiographic and IVUS Analysis at Four-Month and 
One-Year Follow-Up 
Fausto Feres. Alexandre Abizaid, Gerardo Alvar(~z, Rodolfo Staico, Ibraim Pinto, Luiz A. 
Mattos, Ana C. Seixas, Luiz F. Tanajura, Aurea Chaves, Marinella Centemero, Andrea 
Abizaid, Robert Falotico, Judith Jaeger, Amanda Sousa, J. Eduardo Sousa, Institute 
Dante Pazzanese of Cardiology, SaG Pau/o, Brazil 
Background: Sirolimus (Rapamycin) coated stent has been shown to decrease intimal 
hyperplasia (IH) compared to bare stent. 
Objective: To assess the difference of IH between 4 and 12 months of sirolimus-coated 
compared to non-coated (bare) Bx Velocity coronary stents in patients with CAD. 
Methods: Forty-five patients underwent elective, single vessel stenting in our institution. 
Sirolimus-coated stents were implanted in 30 patients (15 fast [15 days] release formula- 
tion and 15 slow [28 days] release of sirolimus) and non-coated stents were implanted in 
15 pts. All stents were 18ram long and 3.0-3.5 mm in diameter. Angiographic and volu- 
metric IVUS analyses were performed by two experience analysts, after the procedure, 
at 4 and 12 month follow-up. 
Results: All stents were successfully deployed after balloon pre-dilatation and pts were 
discharged without complications. Baseline characteristics were similar between groups 
and 23% of the pts had diabetes. Reference vessel diameter was 2.96 _+ 0.3 mm (FR), 
2.98 +- 0.4 (SR) and 2.9_+ 0.4 mm (noncoated stent group], p=NS. 
FR4m FR12m SR 4m SR 12m Bare4m Bare12m 
Late loss (mm) 0.11_+0.11 0.2~0.3 0.05_+0.1 0.08+0.3 0.84+-0.37 0.91:LO.4 
Intimal hyperplasia (mm3) 2.04+_3.8 2.5_+4.3 0.23+-0.89 0.3_+1.3 9.01+~21.5 42.3_+23.5 
FR vs SR: p = NS; FR vs Bare: p< 0.0001; SR vs Bare: p < 0.0001 ; 4 m vs 12 m: p = NS 
Conclusion: Late lumen loss and intimal hyperplasia was virtually absent after implanta- 
tion of sirolimus-coated stents and significantly less than non-coated stents, regardless 
the formulation used (FR versus SR) and the time of follow-up (4 versus 12 months). 
1174-17 Ef fect  on Restenosis With a Pecl i taxel  Eluting Stent: 
Factors Associated With Inh ib i t ion  in the Elutes Cl inical  
Study 
Bernard Chevalier. Ivan De Scheerder, Anthony Gershlick, Edouardo Camezind, Antoine 
Gommeaux, Christian Vrints, Nicholas Reifart, Luc Missault, Jean-Jacques Goy, Alan 
Heldman, Jeffrey Brinker, Albert E. Raizner, The ELUTES Study group, Centre 
Cardio/ogique du Nord, Saint-Denis, France. 
Background: In-stent restenosis remains a clinical problem and the efficacy of drug- 
coated stents is unproven. Paclitaxel inhibits microtubule formation rendering cells cyto- 
static and has been shown to inhibit restenosis in animal models. 
Methods: To evaluate the safety and efficacy of the paclitaxel-eluting V-Flex Plus TM coro- 
nary stent (without polymer coating), a multicenter, randomized, triple-blinded, dose- 
ranging study (ELUTES) with 4 progressive dose treatment groups and one control 
group (uncoated stent) was conducted. In-hospital and 6 month clinical and angiographic 
data were collected. Patients with severe calcification, left main lesion and multiple 
lesions in the target vessel were excluded. Study endpoints were percent diameter 
stenosis and late loss at 6 months measured by QCA, and MACE at I and 6 months. The 
study had independent core lab QCA analysis, clinical events adjudication, and data 
safety monitoring. 
Results: 190 pts received stents (37% LAD, 37% RCA, 21% LCX, 5% RAM). Patients 
were 81% male. Mean age was 60 years. Patients had 56% one- and 27% two-vessel 
disease, 11% unstable angina, 34% prior MI, 2% prior CABG. Lesions were 27% A, 63% 
B1, and 9% B2. There was 1 death, no Q Wave Ml's, no emergent CABG, one re-PTCA 
(0.5%) and 5 (2.6%) non Q ML MACE rate at 30 days was 1.1%. Procedural QCA on 183 
patients and follow-up QCA on 110 patients revealed a reference vessel diameter of 2.96 
+- 0.41mm, a minimum lumen diameter of 0.55 -+ 0.27mm prestent, 2.68 + 0.39 mm post 
stent, and 2.16 _+ 0.78 mm at 6 months. Overall residual stenosis at follow-up was 27.1 +4- 
24.5% and late loss was 0.49 ±0.68 mm including the control group and the four progres- 
sively active groups. Follow-up will be completed in November 2001 after which unblind- 
ing and analysis of clinical, angiographic and procedural factors associated with 
restenosis inhibition will be completed. 
Conclusions: Even without unblinding, a paclitaxel-coated coronary stent with no poly- 
mer appears to be associated with reasonable short-term safety and seems compatible 
with mid-term restenosis inhibition. Unblinding will permit further description of factors 
associated with efficacy at the time of the presentation. 
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1174-18 Are Sirolimus-Eluting Stents Inducing Vascular 
Remodeling? A Subgroup Analysis of 3D-Intrevascular 
Ultrasound in the RAVEL Trial 
Muzaffer Deoertekin, K. Tanabe, E. Regar, J. E. Souse, A, Colombo, G. Guagliumi, J. L. 
Guermonperez, M. C. Morice, P. W. Serruys, Thoraxcenter, Rotterdam, The Netherlands. 
Background: Abolition of intra-stent neointimal hyperplasia after Sirelimus-eluting stent 
(SES) implantation has been demonstrated in a pilot study (FIM: First In Men) and con- 
firmed in the double-blind, randomized, controlled RAVEL tdal. However, the influence of 
SES on plaque burden behind the struts and on the vessel wall (expansion or retraction 
of the external elastic membrane area; EEM) has not been documented. Aim: To com- 
pare vessel remodeling at 6-month follow-up (FU) after SES and uncoated stent (US) 
implantation in a subset of patients randomized in the RAVEL trial at 6 of 19 participating 
centers. Methods: Patients with single de-novo lesions were randomized to receive 
either an 18 mm SES Bx-VELOCITY tm stent (Cordis) or an US Bx-VELOCITY tm stent. 
Motorized IVUS pullback (0.5 mm/sec) was performed at 6-month FU and analyzed by 
an independent core lab (Cardialysis, Rotterdam, NL). Total vessel volume (TVV), stent 
volume (SV), and lumen volume (LV) were measured. Total plaque volume (TPV), plaque 
volume behind the stent (PBS) and neointimal hyperplasia (NIH) were calculated as 
"TVV-LV", "TVV-SV"; "SV-LV", respectively. Data were compared using an unpaired t- 
test, Results: 
Volume (mm 3) SES (n=36) US (n=27) p-value 
TVV 275.7+ 69.1 283.7+71.9 ns 
SV 127.7+- 30.7 138.1 + 36.1 ns 
LV 125.5+_ 32 96.9+ 40.6 0,003 
TPV 150.2+_ 44.4 186.8:1:52.8 0.004 
PBS 148.0+- 45.5 145.6:1:0.41 ns 
NIH 2.18 + 7.2 41.2 + 32,3 O.O00 
Conclusion: PBS and TVV had similar volumes at FU suggesting that no significant 
plaque shrinking or positive/negative remodeling occurred as result of Sirolimus elution. 
in other words, SES is effective in preventing NIH without influencing the vessel wall 
structure when compared with US. 
1174-1 9 SCORE Six-Month Angiogrephic Results: Improved 
Restenosis in Patients Receiving the QUADDS-QP2 
Drug-EluUng Stent Compared With the Control, Bare 
Stents  
Eberhard Grube, Alexandra J. Lanskv. Nicholas Reifarf, Jean Fajadet, Germano 
DiSciascio, Carlo DiMado, Karl Hauptmann, Antonio Colombo, Roland Bach, Sigmund 
Silber, for the SCORE tnvsstigators, Cardiovascular Research Foundation, New York, 
New York, Lenox Hi//Heart and Vascular Institute, New York, New York. 
Background: The QUADDS-QP2 stent is a 316L stainless steel stent that delivers 4000 
ug QP2 (an antiproliferative taxane derivative) from high capacity polymer sleeves. The 
SCORE trial was stopped early due to higher thrombosis with the QP2 Stent after ran- 
domizing 267 of 400 pts with de novo native lesions to a bare metal control stent or the 
QP2 Stsnt (available sizes: 3.0 or 3.5mm; 13 or 17 mm long). Methods: We report the 
quantitative angiographic (QCA) results of the first 260 pts enrolled, with follow-up avail- 
able in 77% (N=202). Restenosis rates (RS) include thrombosis cases (9.4% QP2 vs 0% 
Quest). Results: The stent was deployed successfully in all cases. Lesion characteristics 
were similar at baseline with ACC/AHA class >B1 in 30.9% QP2 vs 33.6% bare stent, 
p=NS (see table). FoUow-up restenosis was reduced by 57%. Conclusion: Despite the 
safety concerns of high dose QP2 delivered via a high capacity polymer on the QUEST 
stent, striking reductions in RS are observed within the targeted stent zone, which 
remains overestimated due to the inclusion of thrombosis cases. Complete adjudicated 6 
month data will be presented. 
QUADDS-QP2 QUEST p value 
N=134 N=126 
Reference, mm 2.92±0.43 3.00±0.48 0.163 
Lesion length, mm 11.67±4.62 11.96±4.36 0.603 
Final MLD, mm 2.28±0.46 2.28±0.53 0.988 
Follow-up Stent MLD, mm 2.31±0.71 1.75±0.79 <0.001 
Stent Late Loss, mm 0.35±0.73 0.65±0.71 0.004 
Restenosls Stent % 10.1% 36.9% <0.001 
1174-20 Treatment of In-Stent Restenosis Using Paclitaxel 
Eluting Stents: Results From the Leuven Pilot Trial 
Ivan De Scheerder, Yanming Huang, Joseph Dens, Lan Wang, xiaoshun Liu, Walter 
Desmet, University Hospitals Leuven, Leuven, Belgium. 
Coronary stents are still hampered by an increased neointimal hyperplasia caused by 
vessel injury due to stent inplantation and due to a foreign body response induced by the 
stent itself. 
Paclitaxsl, extracted from the Pacific Yew Tree, Taxus grevifolia, possess potent immun- 
osuppressive effects, inhibiting cellular activities such as mitosis, migration, endocytosis 
and secretion. 
Pre-clinical investigation with the Cook Paclitaxel-coated coronary stent showed a slow 
in-vivo release of the drug. Fourteen days after stent inplantation in a pig coronary artery, 
69% of the drug was locally released. This resulted in a significant decrease of late loss, 
